期刊
JOURNAL OF CLINICAL PHARMACOLOGY
卷 42, 期 11, 页码 82S-89S出版社
WILEY
DOI: 10.1002/j.1552-4604.2002.tb06007.x
关键词
-
资金
- NCRR NIH HHS [M01 RR00083] Funding Source: Medline
- NIAID NIH HHS [2P30 AI27763] Funding Source: Medline
- NIDA NIH HHS [R01 DA/MH 11607] Funding Source: Medline
Cannabinoids, including smoked marijuana and,Delta(9)-tetrahydrocannabinol (THC) (dronabinol, Marinol), have been used to treat human immunodeficiency virus-1 (HIV)-associated anorexia and weight loss, Concerns have been raised, however, that these compounds might have adverse effects on the immune system of subjects with HIV infection. To determine whether such effects occur, the authors designed a randomized, prospective, controlled trial comparing the use of marijuana cigarettes (3.95% THC) dronabinol (2.5 mg), and oral placebo in HIV-infected adults taking pro-tease inhibitor-containing highly active antiretroviral therapy (HAART). Assays of immune phenotype (including flow cytometric quantitation of T cell subpopulations, B cells, and natural killer[NK] cells) and immune function (including assays for induced cytokine production, NK cell function, and lymphoproliferation) were performed at baseline and weekly thereafter. On the basis of these measurements and during this short 21-day study period, few statistically significant effects were noted on immune system phenotypes or functions in this patient population. Journal of Clinical Pharmacology, 2002.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据